Most Read Articles
29 Nov 2019
Metformin Extended Release 500 mg,750 mg, and 1000 mg
Elvira Manzano, Roshini Claire Anthony, 01 Oct 2019

The European Society of Cardiology (ESC) has released five new guidelines at the ESC Congress 2019, recommending an even lower LDL-C* target in patients at very high risk for cardiovascular disease (CVD), and the use of SGLT2** inhibitors and GLP-1*** receptor agonists as first-line treatments in those with diabetes to reduce their CVD risk.

Roshini Claire Anthony, 16 Dec 2016

Five years of extended therapy with the aromatase inhibitor (AI) letrozole did not improve survival in postmenopausal breast cancer patients, according to findings of the NRG Oncology/NSABP B-42 trial presented at the San Antonio Breast Cancer Symposium (SABCS 2016) held in Texas, US. 

Jackey Suen, 21 Dec 2016

Adding everolimus to fulvestrant in second-line treatment of hormone receptor (HR)-positive, HER2-negative advanced breast cancer improves progression-free survival (PFS) by 40 percent, the phase II PrECOG 0102 study has shown. [SABCS 2016, abstract S1-02]

Letrozole–dasatinib combo shows promise in ER+, HER2– metastatic breast cancer

4 days ago

The combination of the aromatase inhibitor (AI) letrozole plus the Src kinase inhibitor dasatinib appears to be well tolerated and effective, with a clinical benefit rate (CBR) of 71 percent in a cohort of postmenopausal patients with ER-positive, HER2-negative metastatic breast cancer (MBC), according to the results of a noncomparative phase II trial.

The trial randomized 120 patients with 0–1 prior chemotherapy and no previous AI exposure for MBC to receive either letrozole (2.5 mg/day orally; n=63) alone or with dasatinib (100 mg/day orally; n=57). Patients with disease progression on letrozole alone were allowed to crossover to dasatinib plus continued letrozole.

The primary endpoint of clinical-benefit-rate (CBR; complete response plus partial response plus stable disease ≥6 months) with the combination was 71 percent (95 percent confidence interval [CI], 58–83), exceeding the projected rate of 56 percent.

Similarly, the CBR rate of 66 percent (95 percent CI, 52–77) with letrozole alone surpassed the projected 39 percent rate.

In the crossover arm of the combination therapy in patients progressing on letrozole alone, the CBR was 23 percent. Median progression-free survival was higher with the combination than with letrozole monotherapy (20.1 vs 9.9 months).

Letrozole plus dasatinib was well tolerated despite the need to reduce dasatinib dose in 26 percent of patients.

The present data are encouraging and suggest that dasatinib may inhibit the occurrence of acquired resistance to AI therapy, researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
29 Nov 2019
Metformin Extended Release 500 mg,750 mg, and 1000 mg
Elvira Manzano, Roshini Claire Anthony, 01 Oct 2019

The European Society of Cardiology (ESC) has released five new guidelines at the ESC Congress 2019, recommending an even lower LDL-C* target in patients at very high risk for cardiovascular disease (CVD), and the use of SGLT2** inhibitors and GLP-1*** receptor agonists as first-line treatments in those with diabetes to reduce their CVD risk.

Roshini Claire Anthony, 16 Dec 2016

Five years of extended therapy with the aromatase inhibitor (AI) letrozole did not improve survival in postmenopausal breast cancer patients, according to findings of the NRG Oncology/NSABP B-42 trial presented at the San Antonio Breast Cancer Symposium (SABCS 2016) held in Texas, US. 

Jackey Suen, 21 Dec 2016

Adding everolimus to fulvestrant in second-line treatment of hormone receptor (HR)-positive, HER2-negative advanced breast cancer improves progression-free survival (PFS) by 40 percent, the phase II PrECOG 0102 study has shown. [SABCS 2016, abstract S1-02]